Prognostic value of cathepsin D in breast cancer: Comparison of immunohistochemical and immunoradiometric detection methods

Journal of Clinical Pathology

Volumn 49, Issue 1, 1996, Pages 57-64

  Gohring U J ^a   Scharl, A ^a   Thelen, U ^a   Ahr, A ^a   Crombach, G ^a   Titius, B R ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Department of Pathology ^*

Author keywords

Breast cancer; Cathepsin D; Immunohistochemistry; Immunoradiometric assay; Prognosis

Indexed keywords

CATHEPSIN D;

ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TECHNIQUE;

EID: 0030058244     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.1.57     Document Type: Article

References (54)

1. Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D. MCF-7 mammary cancer cells respond to bFGF and internalize it following is release for extracellular matrix: a permissive role of cathepsin-D. Exp Cell Res 1991;194:252-9.
2. Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 1942; 28A/11: 1780-3.
3. Vignon F, Capony F, Chambon M, Freis G, Garcia M, Rochefort H, Autocrine growth stimulation of the MCF 7 breast cancer cell by estrogen-regulated 52 k protein. Endocrinology 1986;118:1537-45.
4. Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L, Rosen PP. Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 1994; 18: 158-66.
5. Crombach G, Ingenhorst A, Göhring U-J, Möbius V, Peters D, Schaeffer H-J, et al. Cathepsin D concentrations in cytosol of benignant and malignant tumors of the breast and female genital tract. Tumordiagn Ther 1993;13:14-18.
6. Crombach G, Ingenhorst A, Göhring U-J, Stützer H, Scharl A. Prognostic significance of cathepsin D in primary breast cancer. Geburtsh Frauenheilk 1991;54:545-51.
7. Granata G, Coradini D, Cappelletti V, Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 1991;27: 970-2.
8. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node negative breast cancer. J Clin Oncol 1993; 11:36-43.
9. Kute TE, Shao Z-M, Sugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for node negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992;52:5198-203.
10. Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouesse J, Maudelonde TH, et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989;ii:1115-8.
11. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, et al. Steroid receptors, pS2 and cathepsin D in early clinically node negative breast cancer. Eur J Cancer 1994;30A:5-11.
12. Tandon AK, Clark GM, Chamnes GC, Chirgwin JM, McGuire WL. Clathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
13. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, et al. Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary breast canter. Canter Res 1989;49:6008-14.
14. Winstanley JHR, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS, Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 1993;67:767-72.
15. Westley B, Rocheford H. Estradiol induced proteins in MCF 7 human breast cancer cell line. Biochem Biophys Res Commun 1979;90:410-6.
16. Garcia M, Capony F, Derocq D, Simon D, Pau R, Rochefort H. Monoclonal antibodies to the estrogen-regulated Mr 52 000 glycoprotein: characterization an immunodetection in MCF7 cells. Cancer Res 1985;45:709-16.
17. Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I, et al. Over-expression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 1989;34:177-82.
18. Cypony F, Moreset M, Barret AJ, Capony JP, Brocqet P, Vignon F, et al. Phosphorylation, glycosylation, and proteolytic activity of the 52-kDa estrogen-induced protein secreted by MCF-7 cells. J Cell Biol 1987;104:253-6.
19. Foucré D, B̈ouchet C, Hacén K, Pourreau-Schneider N, Gentile A, Martin PM, et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 1991; 64:926-32.
20. Garcia M, Salazar-Retana G, Pages A, Richer G, Domergue J, Pages AM, et al. Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res 1986;46: 3734-8.
21. Faust PL, Kornfeld S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 1985;82:4910-4.
22. Maudelonde T, Brouillet JP, Roger P, Giraudier V, Pages A, Rochefort H, Immunostaining of Cathepsin D in breast cancer: quantification by computerised image analysis and correlation with cytosolic assay. Eur J Cancer 1992;28A: 1686-91.
23. Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H, et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993;71:2006-12.
24. Duffy MJ, Reilly D, Brouillet J-P, McDermott FW, Faul C, O'Higgins N, et al. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem 1992;38:2114-6.
25. Remmele W, Sauer-Manthey J. Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch [A] 1993; 422:467-73.
26. Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F, et al. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 1994;25: 863-71.
27. Veneroni S, Daidone MG, Di-Fronzo G, Cappelletti V, Amadori D, Riccobon A, et al. Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breat Cancer Res Treat 1993; 26:7-13.
28. Eng-Tan P, Benz CC, Dollbaum C, Moore DH, Edgerton SM, Zava DT, et al. Prognostic value of cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 1994;5:329-30.
29. Göhring U-J, Ingenhorst A, Crombach G, Scharl A. Kathepsin-D-Expression im primären Mammakarzinom-Vergleich immunhistochemischer und biochemischer Ergebnisse. Pathologe 1993;14:313-7.
30. Scharl A, Vierbuchen M, Würz H. Immunhistochemischer Nachweis von Östrugen-und Progesteronrezeptoren mit Hilfe monoklonaler Antiköper in Mammakarzinomge weben. Vergleich mit der biochemischen Rezeptoranalyse. Pathologe 1989;10:31-8.
31. Hsu S-M, Raisse L, Fanger H, Use of avidin-biotin-peroxidase-complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1081;29:577-80.
32. EORTC Breast Cancer Cooperative Group. Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 1973;9:379-81.
33. Lowry DH, Rosebrough NJ, Farr AL, Handel RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
34. Peto R, Pike MC, Armitage P. Design and analyses of randomised clinical trials requiring prolonged observation of each patients: II. Br J Cancer 1977;35:1-39.
35. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-200.
36. Mansour EG, Rvdin PM, Dressler L. Prognostic factor in early breast carcinoma. Cancer 1994;74:381-400.
37. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990; 82:1006-15.
38. Rosner D, Larie WW. Should all patients with node negative breast cancer receive adjuvant therapy? Cancer 1991;68: 1482-94.
39. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:115;71-85.
40. Garcia M, Lacombe MJ, Duplay H, Cavailles V, Derocq D, Delarue JC, et al. Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 1987;27:439-45.
41. Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/Mannose-6-Phosphate Receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 1990;4:1327-35.
42. Rochefort H, Capony F, Garcia M. Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells 1990;2:383-8.
43. Henry JA, McCarthy AL, Angus B, Westley HR, May FEB, Nicholsin S, et al. Prognostic significance of the estrogen-reglated protein, cathepsin D, in breast cancer - an immunohistological study. Cancer 1990;65:265-71.
44. Tetu B, Brisson J, Cöté C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin-D expression in node positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993;55:429-35.
45. Visscher DW, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, et al. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 1993; 6: 302-6.
46. Namer M, Ramaioli A, Fontana X, Etienne M-C, Héry M, Jourlait A, et al. Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 1991;19:85-93.
47. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, et al. The relative prognostic significance of total cathepsin 15 and HER-2/neu oncogene amplification in breast cancer. Int J Cancer 1994;56:61-5.
48. Rogier H, Freiss G, Besse M-G, Cavalié-Barthez G, Garcia M, Pau B, et al. Two-site immunoenzymometric assay for the 52-kDa cathepsin D in cytosols of breast cancer tissues. Clin Chem 1989;35:81-5.
49. Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positiv. Virchows Arch [A] 1993;423:497-502.
50. Kandulafi PL, Chang KL, Ahn CW, Traweek ST, Mehra P, Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 1993;71:2756-63.
51. Cowan WK, Angus B, Henry J, Corbett LP, Reid WA, Horne CHW. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 1991;64: 780-4.
52. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Human Pathol 1994;25:857-62.
53. Martinet N, Beck G, Bernard V. Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity. Cancer 1992;70:855-60.
54. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, et al. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node negative breast cancer. J Clin Oncol 1994;12:467-74.